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Summary
Background: In Japan, the recent status of the mortality of atrial ﬁbrillation (AF) patients is
still unclear.
Methods and results: We used a single-hospital based cohort database in an urban city (Tokyo)
in Japan, including all the new visitors from 2004 to 2009 (n = 13,228). The non-adjusted death
rates of AF patients for all-cause, stroke, and cardiovascular death were 1091, 97, and 727
per 100,000 patient-years, and the age-adjusted ones were 317 (95% CI, 316—318), 16 (95%
CI, 16—16), and 238 (95% CI, 237—239), respectively. The age-adjusted relative risk of AF on
all-cause mortality was 1.7 in the particular population.
Conclusions: The present study provides the most recent data about the characteristics and the
mortality of AF patients in Tokyo, thus serving as the basic information for ﬁnding problems to
solve regarding Japanese AF patients.
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he developed countries, and its prevalence almost doubles
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ith each decade of life [1—3] leading up to 25% on a lifetime
asis [4]. Several reports have noted that the AF population
ill greatly increase in the future according to the rise in age
f society [3,5,6]. Thus, AF is becoming an epidemiologically
mportant arrhythmia both in Western countries [3] and in
apan [5,6].Moreover, AF has been known to be an important risk
actor for increasing mortality [7,8], and the mortality risk
or AF has been identiﬁed as approximately 1.5—2 times both
n Western countries [7,9] and Japan [10]. Besides, in the
Published by Elsevier Ltd. All rights reserved.
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cMortality of AF in Japan
reports of Western countries, the mortality of AF patients
at 1 year after the ﬁrst diagnosis has been identiﬁed as over
10% [7,9].
To improve the mortality of AF, many efforts have been
made, including sinus restoration [11], the controlling of
heart rate, and the management of accompanying cardio-
vascular diseases [12,13], including the prevention of stroke
[14]. Consequently, several reports clariﬁed that the mortal-
ity of AF has improved in the recent two or three decades
at least in particular settings [15—19]. This updated infor-
mation regarding the real-world status of AF patients could
provide an aid for ﬁnding the next well-directed tasks to
solve.
However, in Japan, the recent status of the mortality
of AF patients is still unclear because only scarce reports
[10,20] have identiﬁed the mortality. Besides, it has already
been several decades since the previous data have been
started [10]. In this situation, we aimed to identify the
recent mortality of AF patients in a single hospital-based
cohort in an urban city of Japan. Although the population
is restricted to a particular setting, the data provide the
most recent status regarding the mortality of AF patients in
Japan.
Methods
Study patients
The Shinken Database was established comprising all the
new patients visiting the Cardiovascular Institute Hospi-
tal in Tokyo, Japan (‘‘Shinken’’ is an abbreviated name
in Japanese for the name of the hospital), and excluded
patients with active cancer and any foreign travellers. The
principle aim of this hospital-based database is a surveil-
lance of the prevalence and prognosis of cardiovascular
diseases in the urban areas of Japan [20]. The registry
started in June 2004, and thereafter patients have been
continually registered to the database annually.
The data in the present study was derived from this
database between June 2004 and March 2010 (Shinken
Database 2004—2009) including 13,228 new visiting patients
(AF was diagnosed in 1942 patients).
Data collection at initial visit
In each patient, after obtaining an electrocardiogram and
chest X-ray, the cardiovascular status was evaluated using
echocardiography, an exercise test, 24-h Holter recordings,
and blood laboratory data within 3 months after the initial
visit, according to the decision by the attending physicians.
The information regarding medications was obtained from
the hospital database within 3 months after the initial visit.
Details have been published elsewhere [20,21].
Patient follow-upThe health status and the incidence of cardiovascular events
and mortality are maintained in the database by being linked
to the medical records of the hospital, and by study docu-
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ents of prognosis sent once per year to those who stopped
ospital visits or who were referred to other hospitals.
In the present data analysis, the follow-up data after
pril 1st, 2010 were excluded. Therefore, the end of the
ollow-up period was deﬁned as one of the following three:
1) the date of death, if the date was prior to March 31st,
010; (2) the ﬁnal hospital visit or the ﬁnal response to our
tudy documents of prognosis with the conﬁrmation of being
live prior to March 31st, 2010; and (3) March 31st, 2010,
hen the date of death, the ﬁnal hospital visit, or the ﬁnal
esponse to our study documents of prognosis were later
han April 1st, 2010.
thics
he ethical committee at the Cardiovascular Institute
ranted ethical permission for this study and all the patients
ave written informed consent.
eﬁnition of AF
n the present study, AF was diagnosed by electrocardio-
raphic recordings, including 12-lead surface electrocardio-
rams and 24-h Holter recordings within the 3 months after
he initial visit, and by the medical history of AF from the
eferring physicians. New-onset AF later than 3 months after
he initial visit was not included in the diagnosis of AF in the
resent study.
iagnosis of death
e conﬁrmed deaths of study patients by the medical
ecords of our hospital or by the information obtained from
ollow-up. Deaths from stroke (both of ischemic and haem-
rrhagic) and cardiovascular diseases were deﬁned when the
auses of death were classiﬁed into ICD 10 code numbers of
60-I69 and I00-I99, respectively [10].
tatistical analysis
n the patients’ background, the categorical and consecu-
ive data are presented as number (%) and mean± standard
eviation, respectively. The chi-square test was used for the
roup comparison, and the unpaired t-test and the one-way
nalysis of variance were used for the comparison of the
onsecutive variables between 2 groups and more than 2
roups, respectively. The crude death rates of AF patients
ere compared with those of non-AF patients, calculating
he relative risk and the 95% conﬁdence intervals both in the
otal population and in the separated age-stratiﬁcations.
Thereafter, the age-adjusted death rates of AF patients
ere calculated using the Japanese standard population
odel of 1985. Then, age-adjusted relative risks were cal-
ulated using the Mantel-Haenszel method adjusted by age
ategories.These analyses were performed using SPSS (SPSS Inc.,
hicago, IL, USA) for Windows (Microsoft Corp., Redmond,
A, USA), version 14.0 software. Statistical signiﬁcance was
et at two-sided p-value of <0.05.
1 S. Suzuki et al.
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Figure 1 Crude death rates in age stratiﬁcations of patients
with and without atrial ﬁbrillation (AF): Shinken Database
2004—2009. Crude death rates for (a) all-cause, (b) stroke, and
(c) cardiovascular death of patients with and without AF are
shown in age stratiﬁcations.
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haracteristics of the study patients
he characteristics of the study patients (AF 1942 and non-
F 11,286) are shown in Table 1. AF patients in the present
tudy included 1426 men (73%) and had a mean age of
6.4 years. Among them, co-existing organic heart diseases,
ymptomatic heart failure (New York Heart Association II),
ystolic dysfunction [left ventricular ejection fraction (LVEF)
40], hypertension, diabetes mellitus, and history of cere-
ral infarction or transient ischemic attack (TIA) existed in
66 (34%), 395 (20%), 148 (8%), 853 (43%), 341 (18%), and 123
6%), respectively. The prescription rates of class I, II, III and
V anti-arrhythmic drugs in AF patients were 27%, 32%, 3%,
nd 23%, respectively, and digitalis was prescribed in 18%.
arfarin and antiplatelet drugs were prescribed in 46% and
2% of AF patients, respectively. As compared with non-AF
Table 1), age, the prevalence of co-existing organic heart
iseases, heart failure, hypertension, diabetes mellitus and
he history of cerebral infarction or TIA were signiﬁcantly
igher in AF patients, except for ischemic heart disease.
The characteristics of the AF patients in age-
tratiﬁcations by decade are shown in Table 2. The
revalence of co-existing diseases signiﬁcantly increased as
ge progresses, while that of cardiomyopathy and systolic
ysfunction (LVEF 40%) was highest in the stratiﬁcation
f 40—49 years. The prescription rates of anti-arrhythmic
rugs also signiﬁcantly increased according to increment of
ge, except for class III drugs.
rude death rate
he average follow-up periods of AF and non-AF patients
ere 775.5± 622.8 days and 687.4± 612.8 days, respec-
ively. The crude death rates for all-cause, stroke, and
ardiovascular death with AF patients were 1091, 97, and
27 per 100,000 patient-years, approximately twice as high
s those of non-AF patients (522, 47, and 362 per 100,000
atient-years, respectively).
The crude death rates of AF and non-AF patients in
ge-stratiﬁcations are shown in Fig. 1. The death rates for
ll-cause, stroke and cardiovascular death with AF patients
n separated age-stratiﬁcations by decade steadily increased
rom all 0 in 20—29 years to 2241, 303, and 1664 per 100,000
atient-years in 80 years, respectively. Meanwhile, the
ge-stratiﬁed death rates for all-cause, stroke, and cardio-
ascular death with non-AF patients were at a low level
efore 69 years and then increased to 2195, 179, and 1523
er 100,000 patients-years in 80 years, respectively.
The relative risks of the death rates between AF and
on-AF patients are shown in Table 3. That for all-cause
eath between AF and non-AF patients was 3.38 (95% CI,
.13—10.0) in 50—59 years, then gradually decreased with
ncreasing of age to 1.10 (95% CI, 0.63—1.92) in 80 years.
hat for stroke death was 5.08 (95% CI, 0.31—81.2) in 60—69
ears, then decreased to 0.99 (95% CI, 0.11—8.85) in 70—79
ears, and 1.68 (95% CI, 0.30—9.19) in 80 years. That for
ardiovascular death was 4.86 (95% CI, 1.31—18.0) in 50—59
ears, then gradually decreased to 1.09 (95% CI, 0.55—2.14)
n 80 years. The relative risks were incomputable under
a
1
r0—49 years for all-cause death and for cardiovascular death
nd under 50—59 years for stroke death, because the number
f deaths was small either in AF or non-AF patients.
ge-adjusted mortality
e calculated the age-adjusted death rates for all-cause,
troke, and cardiovascular death with the AF and the non-
F patients in the present study. The age-adjusted death
ates for all-cause, stroke, and cardiovascular death were
17 (95% CI, 316—318), 16 (95% CI, 16—16), and 238 (95%
I, 237—239) per 100,000 patient-years in AF patients and
82 (95% CI, 181—183), 12 (95% CI, 11—12), and 141 (95%
I, 140—141) per 100,000 patient-years in non-AF patients,
espectively.
The age-adjusted relative risks of AF of all-cause, stroke,
nd cardiovascular death were 1.71 (95% CI, 1.20—2.43),
.61 (95% CI, 0.50—5.16), and 1.64 (95% CI, 1.07—2.52),
espectively.
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Table 1 Characteristics of study patients with/without atrial ﬁbrillation: Shinken Database 2004—2009, Tokyo, Japan.
Characteristics AF (n = 1942) Non-AF (n = 11,286) p-Value Total (n = 13,228)
Men 1426 (73) 6637 (59) <0.001 8063 (61)
Age, yrs 66.4± 12.7 59.6± 15.6 <0.001 60.6± 15.4
Body mass index, kg/m2 23.6± 3.4 23.3± 4.2 <0.001 23.4± 4.1
Organic cardiac diseases 666 (34) 3000 (27) <0.001 3666 (28)
Valvular heart disease 410 (21) 883 (8) <0.001 1293 (10)
Ischemic heart disease 187 (10) 1813 (16) <0.001 2000 (15)
Myocardial infarction 77 (4) 630 (6) 0.004 707 (5)
Cardiomyopathy 195 (10) 529 (5) <0.001 724 (6)
Othersa 34 (2) 124 (1) 0.020 158 (1)
Heart failure
NYHA II 395 (20) 853 (8) <0.001 1248 (9)
LVEF 40 148 (8) 338 (3) <0.001 486 (4)
Other co-existing diseases
Hypertension 835 (43) 4298 (38) <0.001 5133 (39)
Diabetes mellitus 341 (18) 1584 (14) <0.001 1925 (15)
Chronic kidney disease 546 (28) 1620 (14) <0.001 2166 (16)
History of cerebral infarction/TIA 123 (6) 200 (2) <0.001 323 (2)
CHADS2 score <0.001
0 pts 664 (34) 5558 (49) 6222 (47)
1 pts 610 (31) 3316 (29) 3926 (30)
2 pts 394 (20) 1723 (15) 2117 (16)
3 pts 187 (10) 536 (5) 723 (6)
4 pts 66 (3) 113 (1) 179 (1)
5 pts 14 (1) 28 (0) 42 (0)
6 pts 7 (0) 12 (0) 19 (0)
Medications for rate control
Class II anti-arrhythmic drug 618 (32) 1413 (13) <0.001 2031 (15)
Class IV anti-arrhythmic drug 440 (23) 532 (5) <0.001 972 (7)
Digitalis 345 (18) 121 (1) <0.001 466 (4)
Medications for rhythm control
Class I anti-arrhythmic drug 523 (27) 271 (2) <0.001 794 (6)
Class III anti-arrhythmic drug 51 (3) 55 (1) <0.001 106 (1)
Medications for anti-thrombosis
Warfarin 899 (46) 497 (4) <0.001 1396 (11)
PT-INR at the initial visitb 1.4± 0.5 1.3± 0.4 0.001 1.4± 0.5
PT-INR at 6th monthb 1.8± 0.7 1.8± 0.5 0.505 1.8± 0.7
PT-INR at 12th monthb 1.9± 0.5 1.9± 0.5 0.665 1.9± 0.5
Antiplatelet drugs 820 (42) 2424 (22) <0.001 3244 (25)
AF, atrial ﬁbrillation; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack; PT-INR,
prothrombin time-international normalized ratio.
The categorical and consecutive data are presented as number (%) and mean± standard deviation, respectively.
a Other organic heart diseases include congenital heart disease and left ventricular non-compaction.
b PT-INR values were available in 642/411, 302/103 and 198/66 AF/non-AF patients at the initial visit, the 6th and the 12th month,
p
r
p
r
A
frespectively.
Discussion
Major ﬁndings
In the present study, we identiﬁed the non-adjusted and
age-adjusted death rates of AF and non-AF patients in a
cardiovascular hospital in an urban city of Japan. The non-
adjusted death rates of AF patients for all-cause, stroke, and
cardiovascular death were 1091, 97, and 727 per 100,000
patient-years, and the age-adjusted ones were 317 (95% CI,
316—318), 16 (95% CI, 16—16), and 238 (95% CI, 237—239)
C
I
ter 100,000 patient-years, respectively. The age-adjusted
elative risk of AF on the all-cause mortality was 1.7 in this
articular population. The present study provides the most
ecent data about the characteristics and the mortality of
F patients in Tokyo, thus serving as the basic information
or ﬁnding problems to solve.omparison with previous studies
n previous Western reports, the relative risk of AF on mor-
ality has been identiﬁed as approximately 1.5—2 times
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Table 2 Characteristics of atrial ﬁbrillation patients by age stratiﬁcations: Shinken Database 2004—2009, Tokyo, Japan.
Characteristics Age (years)
20—29 30—39 40—49 50—59 60—69 70—79 80 p value
(n = 3) (n = 48) (n = 145) (n = 328) (n = 612) (n = 503) (n = 303)
Men 3 (100) 40 (83) 131 (90) 294 (90) 467 (76) 320 (64) 171 (56) <0.001
Age, yrs 24.7± 2.5 35.0± 2.6 45.1± 2.9 55.2± 2.9 64.7± 2.9 74.2± 2.8 84.7± 4.3
Body mass index, kg/m2 27.1± 5.1 23.7± 3.7 24.2± 3.8 24.7± 3.3 23.8± 3.3 23.3± 3.3 22.5± 3.6 <0.001
Organic cardiac diseases 0 (0) 10 (21) 35 (24) 83 (25) 173 (28) 224 (45) 141 (47) <0.001
Valvular heart disease 0 (0) 3 (6) 15 (10) 43 (13) 98 (16) 146 (29) 105 (35) <0.001
Ischemic heart disease 0 (0) 0 (0) 1 (1) 13 (4) 48 (8) 68 (14) 57 (19) <0.001
Myocardial infarction 0 (0) 0 (0) 1 (1) 7 (2) 19 (3) 27 (5) 23 (8) <0.001
Cardiomyopathy 0 (0) 3 (6) 17 (12) 40 (12) 65 (11) 47 (9) 23 (8) 0.452
Othersa 0 (0) 4 (8) 5 (3) 9 (3) 5 (1) 9 (2) 2 (1) 0.001
Heart failure
NYHA II 0 (0) 4 (8) 22 (15) 48 (15) 104 (17) 124 (25) 93 (31) <0.001
LVEF 40 0 (0) 2 (4) 15 (10) 22 (7) 43 (7) 41 (8) 25 (8) 0.723
Other co-existing diseases
Hypertension 0 (0) 4 (8) 13 (9) 103 (31) 251 (41) 283 (56) 181 (60) <0.001
Diabetes mellitus 0 (0) 0 (0) 8 (6) 39 (12) 117 (19) 114 (23) 63 (21) <0.001
Chronic kidney disease 0 (0) 0 (0) 9 (6) 47 (14) 155 (25) 184 (37) 152 (50) <0.001
History of cerebral infarction/TIA 0 (0) 0 (0) 4 (3) 12 (4) 30 (5) 47 (9) 30 (10) <0.001
Medications for rate control
Class II anti-arrhythmic drug 0 (0) 13 (27) 47 (32) 118 (36) 191 (31) 172 (34) 77 (25) 0.070
Class IV anti-arrhythmic drug 1 (33) 11 (23) 40 (28) 81 (25) 134 (22) 111 (22) 62 (20) 0.660
Digitalis 0 (0) 1 (2) 22 (15) 37 (11) 97 (16) 115 (23) 73 (24) <0.001
Medications for rhythm control
Class I anti-arrhythmic drug 1 (33) 15 (31) 49 (34) 87 (27) 201 (33) 122 (24) 48 (16) <0.001
Class III anti-arrhythmic drug 0 (0) 0 (0) 4 (3) 12 (4) 16 (3) 16 (3) 3 (1) 0.159
Medications for anti-thrombosis
Warfarin 1 (33) 7 (15) 59 (41) 112 (34) 279 (46) 282 (56) 159 (52) <0.001
Antiplatelet drugs 0 (0) 14 (29) 48 (33) 135 (41) 273 (45) 220 (44) 130 (43) 0.050
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack.
The categorical and consecutive data are presented as number (%) and mean± standard deviation, respectively.
a Other organic heart diseases include congenital heart disease and left ventricular non-compaction.
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Table 3 Relative risks of atrial ﬁbrillation on mortality
in age stratiﬁcations: Shinken Database 2004—2009, Tokyo,
Japan.
Relative risks of atrial
ﬁbrillation on
mortality [95% CI]
Age stratiﬁcations
20—29
All-cause death - - -a
Stroke death - - -a
Cardiovascular death - - -a
30—39
All-cause death - - -a
Stroke death - - -a
Cardiovascular death - - -a
40—49
All-cause death - - -a
Stroke death - - -a
Cardiovascular death - - -a
50—59
All-cause death 3.38 [1.13—10.0]
Stroke death - - -a
Cardiovascular death 4.86 [1.31—18.0]
60—69
All-cause death 2.69 [1.20—6.02]
Stroke death 5.08 [0.31—81.2]
Cardiovascular death 2.11 [0.74—6.00]
70—79
All-cause death 1.68 [0.90—3.13]
Stroke death 0.99 [0.11—8.85]
Cardiovascular death 1.55 [0.71—3.34]
80
All-cause death 1.10 [0.63—1.92]
Stroke death 1.68 [0.30—9.19]
Cardiovascular death 1.09 [0.55—2.14]
Total
All-cause death 2.08 [1.47—2.94]
Stroke death 2.06 [0.64—6.56]
Cardiovascular death 2.00 [1.31—3.05]
CI, conﬁdence intervals.
a Relative risks of atrial ﬁbrillation on mortality for any types of
death in 20s, 30s, and 40s age-categories and for stroke death in
50s age-category were not calculated, because of the small num-
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ober of deaths in either of patients with/without atrial ﬁbrillation
in the categories.
[7,9]. Also in a previous Japanese report, the relative risk of
AF on mortality was identiﬁed as approximately twice [10].
In the present study, the age-adjusted relative risk of AF on
mortality was approximately 1.7 times, mostly compatible
to the previous reports both in Western countries [7,9] and
in Japan [10].
However, the death rates of AF patients themself vary
according to the nations and also according to the popu-
lations. In the Framingham study [7], 61.5% of AF patients
aged 55—74 years died at 10 years of follow-up in men and
57.6% died in women. Moreover, in the population, over 90%
of AF patients aged 85—94 years died at 10 years of follow-
up, both men and women. In another report from the USA
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egarding ﬁrst detected AF [9], the Kaplan-Meier estimate
f survival at 4 months was 83% (mortality 17%) and that at 5
ears was 52% (mortality 48%). However, in Japan, the report
f a nationwide, general population-based cohort (NIPPON
ATA 80) [10] identiﬁed that the age-adjusted death rates
or all-cause death in AF patients was 2173 per 100,000
atient-years (2.2% per year), much lower than those of
he Western reports. Furthermore, in the present study of
ospital-based cohort in an urban area of Japan, the age-
djusted death rates for all-cause death in AF patients was
17 per 100,000 patient-years (0.3% per year), further lower
han that of NIPPON DATA 80 [10].
The lower mortality of AF patients in the present study
ompared to the previous Western and Japanese reports
ight be derived from many reasons. First, it would be
ikely that the difference is derived from the difference
f the patients’ backgrounds. Approximately 30—40% of AF
atients have ischemic heart disease in Western countries
9,19,22] compared with ∼10% in our database. Further-
ore, ∼20% also had myocardial infarction in Western
ountries [9] compared with only 4% in our database.
esides, approximately twice as many AF patients in West-
rn reports [9,19,22] had a history of cerebral infarction
r TIA compared to our database. Also, the prevalence of
ypertension in the Western studies [19,22] is 1.5 times to
wice of that of ours. These differences in patients’ back-
rounds might be affected by the variations of lifestyles,
ealth insurance, and hospital access according to coun-
ries or to locations, and the difference should lead to the
ifferent prognosis.
Second, there seem to be differences derived from
he study style between the general population and the
ospital-based cohort. Several reports from Western coun-
ries [15—19] have demonstrated that the mortality of AF
atients in hospital-based cohorts has been signiﬁcantly
mproved, although that in the general population has not
9]. It should be remembered that, in the general popula-
ion, the majority of mortality events with AF patients occur
ithin 30 days after the initial detection [7,9]. It suggests
hat critical patients in this very early phase might be miss-
ng in the cardiovascular hospitals like ours. Such inherent
election bias in hospital-based cohorts could result in the
ifference in mortality compared to the general population.
Third, the difference could be derived also from the dif-
erence of the time. It has already been several decades
ince the previous studies were started [7,9,10], and there
ave been numerous changes in the management of car-
iovascular diseases, including heart failure, stroke, and
oronary artery disease, as well as AF itself. Notably,
trongly inﬂuenced by the AFFIRM [23] and RACE studies
24] and emphasis on the importance of anticoagulation for
troke prevention, the prescription rate of warfarin with AF
atients in Japanese cardiovascular hospitals substantially
ncreased from 14% in the 1990s [25] to 49% in the 2000s [20].
onsidering these changes, it is conceivable that mortality
f AF progressively improved in recent decades.elative risks of AF in age-stratiﬁcations
n the present study, we report that the relative risks of AF
n the mortality were inversely related to the increasing
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f age. Although it seems to be paradoxical, we can notice
hat it was similarly observed in the data of the Framing-
am study [7]. The inverse relationship might derive from
he characteristics in the background of AF patients, where
he prevalence of severe heart failure (with decreased left
entricular function) was relatively high in younger patients
Table 2). Considering that the mortality rates for cardio-
ascular death, but not for stroke death, in the younger age
roups were higher in AF patients than in non-AF patients
Fig. 1), non-stroke cardiovascular death, including severe
eart failure with cardiomyopathy, might be the remaining
arget to improve the mortality of AF in the future.
linical implications
urrently, there have been several discussions on what are
he main tasks to be solved in the management of AF
atients. The discussions have been diverse, from reducing
he incidence of mortality, stroke, and hospital admissions
o improvement of quality of life. Recently in Japan, sev-
ral clinical trials have been conducted with AF patients
26—28]. Although these trials should require the basic
nformation regarding the real-world status of Japanese AF
atients, including the mortality, morbidity, and quality of
ife, such data have been still scarce in Japan.
The present study identiﬁed that the mortality of AF
atients, at least in a hospital-based cohort of an urban
ity area, was extremely low. Although the results could
ot be easily expanded to the nationwide hospitals or to
he general population, our results would imply that studies
egarding Japanese AF patients should include several com-
ined endpoints other than mortality alone, when they deal
ith Japanese AF patients in urban areas. Otherwise, when
e aim to improve the mortality of Japanese AF patients,
e should deﬁne a particular population of Japanese AF
atients to be adapted to the task, which is linked to par-
icular patients’ backgrounds.
imitations
he results of the present study have several limitations in
he methodologies. First, our database excluded patients
ith active cancer which strongly inﬂuences the all-cause
ortality. Actually, in the AFFIRM study [29], cancer-related
eath represented nearly one-sixth and one-fourth of total
ortality in the rate-control and in the rhythm-control arm
f AF patients, respectively. Therefore, excluding those with
ctive cancer in the present study, would lead to underes-
imate the actual mortality rates. Second, because of the
ndications in consultation for a single-department cardio-
ascular hospital, it is likely that patients who were ﬁrstly
iagnosed as having AF with severe stroke or end-stage
enal disease were not seen in our database. These high-
isk diseases frequently coincide with new-onset AF [30,31],
nd such high-risk AF patients are closely associated with
ncreased mortality. Therefore, it should be noted that the
F patients in the present study might be, at least to some
xtent, limited to those that had survived the risky early
hase [7,9]. Third, the number of events was relatively small
n the present study. Therefore, only several events might
ave changed part of the results.
[S. Suzuki et al.
onclusions
ur data identiﬁed the current status of the mortality of
F patients in a cardiovascular hospital in an urban city of
apan. The current mortality of AF patients in an urban city
rea was still lower than that in a previous Japanese report,
uggesting, at least in part, a recent improvement in mor-
ality with advancement in therapy. However, the results
hould be interpreted based on the recognition of the pos-
ible differences between hospitals and general population
nd those between urban areas and rural ones. Although lim-
ted, it would be noteworthy that the present study provides
he most recent data regarding mortality of AF patients in
apan.
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